Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6® cell line in its ‘UMN-03' project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.
